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Background: A variety of innate subsets of lymphoid cells such as natural killer (NK) cells, several pop-
ulations of innate lymphoid cells (ILCs), and mucosal-associated invariant T (MAIT) cells as innate-like T
lymphocytes are involved in asthma and may have important effector functions in asthmatic immune
responses. In the present study, we investigated whether NK cells, ILCs, and MAIT cells in the peripheral
blood of patients with asthma would be associated with clinical asthma parameters.
Methods: We recruited 75 adult patients with mild to severe asthma. The peripheral blood mononuclear
cells in peripheral venous blood samples from the patients were puriﬁed and stained with different
combinations of appropriate antibodies. The cells were analyzed by ﬂow cytometry.
Results: The percentage of activated (i.e., CD69þ) NK cells in the total NK cell population was negatively
correlated with FEV1% which is calculated by the forced expiratory volume in 1 s (FEV1)/the forced vital
capacity (FVC). The percentages of CD69þ ILC1s and ILC2s were negatively correlated with FEV1% and %
FEV1. The percentage of CD69þ ILC3s was positively correlated with BMI, and the percentage of CD69þ
MAIT cells was negatively correlated with FEV1%. Moreover, the percentage of CD69þ NK cells, ILC1s,
ILC2s, ILC3s, and MAIT cells were positively correlated with each other.
Conclusions: For the ﬁrst time, our data showed that activated NK cells, ILC1s, ILC2s, ILC3s, and MAIT cells
were positively correlated with each other and may be associated with airﬂow limitation in patients with
asthma.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
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Allergic asthma is characterized by chronic airway inﬂam-
mation, increased mucus production in the bronchioles, and
airway hyperreactivity to a variety of speciﬁc and nonspeciﬁc
stimuli. Several cell types are involved in airway inﬂammation;
however, acquired immunity and antigen-speciﬁc Th2 cells,
which secrete Th2 cytokines such as interleukin (IL)-4, IL-5,
and IL-13 may drive asthma pathobiology.1e4 The concentra-
tion of Th2 cytokines appears to be correlated with the severity
of disease. These cytokines are responsible for the recruitment
and activation of other cell types such as eosinophils, which
have been associated with lung injury. The Th2 immune re-
sponses also mediate the production of mucus by the airway
epithelium, which contributes to airway obstruction that con-
stitutes a major component of the pathology of allergic airway
inﬂammation.5e7 In contrast to the enormous receptor diversity
of T cell antigen receptors (TCRs) on conventional T cells,
several lymphocyte subpopulations with limited repertoire di-
versity have been identiﬁed such as mucosal-associated
invariant T (MAIT) cells.8,9 The MAIT cells constitute an abun-
dant population of innate-like T cells that express a semi-
invariant TCR and have been reported to be involved in
various disease conditions including infections and autoim-
mune diseases.10e12
The “innate” subsets of lymphoid cells are divided into
innate-like T lymphocytes, which express a semi-invariant TCR,
and innate lymphoid cells (ILCs), which lack TCRs.13 The ILCs
also lack myeloid cell markers and dendritic cell phenotypical
markers.13 Several distinct ILC populations have recently been
identiﬁed that are similar to natural killer (NK) cells, which are
the prototypical ILC population. Several reports have been
proposed to classify ILC populations based on their phenotyp-
ical and functional characteristics.13,14 The nomenclature is
based on helper T cell nomenclature and categorizes the ILC
populations into three groups: (1) group 1 ILCs (ILC1s), which
consists of ILCs that produce interferon g (IFN-g); (2) group 2
ILCs (ILC2s), which produces type 2 cytokinesdin particular IL-
5 and IL-13; and (3) group 3 ILCs (ILC3s), which produce Il-17
and/or IL-22. In this model, NK cells are classiﬁed as ILC1s.13,14
Studies have highlighted many roles for ILCs and innate-like T
cells in regulating the immune system. The cells are hetero-
geneous in their tissue location, cytokine production, and
effector functions.15e18
Mucosal-associated invariant T cells are abundant in human
peripheral blood where they usually represent 1e10% of the total
ab T cell population. These cells also exist in the gut mucosa,
liver, and lung.9,19e24 The ILC2s were also initially described in
gut and lung, and ILC2s have been detected in human peripheral
blood from healthy and asthmatic people.25e29 Thus, in the
present study, we investigated whether the frequency of NK cells,
ILCs, and MAIT cells in peripheral blood in patients with asthma
was associated with clinical asthma parameters.A, et al., Circulating activated
ts with asthma, Allergology InMethods
Patients
The patients were recruited from our outpatient clinic at Jun-
tendo University Hospital (Tokyo, Japan). Patients were enrolled
who had mild to severe asthma and were aged 20 years or older.
Asthma was diagnosed by a compatible clinical history of episodic
symptoms with airﬂow limitation and by variations in pulmonary
function monitored by forced expiratory volume in 1 s (FEV1) or
peak expiratory ﬂow (PEF) in accordance with the Global Initiative
for Asthma (GINA) guidelines.30 The severity of disease in eligible
patients was also assessed in accordance with the GINA guide-
lines.30 The present study was reviewed and approved by the
Juntendo University Research Ethics Committee (Tokyo, Japan).
Written informed consent was obtained from each patient before
their participation in the study. This study was registered in the
UMIN Clinical Trial Registry (UMIN000009968) on February 5, 2013
(http://www.umin.ac.jp/).
Patients having any of the following criteria were excluded: a
diagnosis of chronic obstructive pulmonary disease (COPD), as
deﬁned by the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines, and any current respiratory disorder other
than asthma.31
The asthma control test (ACT) score; pulmonary function
tests, which includes respiratory resistance and reactance by the
forced oscillation technique (FOT); and the fractional exhaled
nitric oxide (FeNO) levels were measured. The FeNO levels were
measured in accordance with the American Thoracic Society
recommendations at a constant ﬂow of 0.05 L/s against an
expiratory resistance of 20 cm water with a chemiluminescence
analyzer (NOA 280i; Sievers, Boulder, CO, USA). The FOT was
measured using the MostGraph-01 FOT device (Chest MI, Tokyo,
Japan).Flow cytometry
Peripheral venous blood samples were collected in heparin-
containing tubes and plasma was frozen at 80 C immediately af-
ter centrifugation for the measurement of periostin levels. Periph-
eral bloodmononuclear cells (PBMCs; at 3106/well)were puriﬁed
by density-gradient centrifugation using FicollePaque Plus solution
(GE Healthcare, Tokyo, Japan). The cells were stained with different
combinations of appropriate antibodies for 30 min at 4 C. The
following surface marker antibodies were used in this study: anti-
CD11c-FITC (BioLegend, San Diego, CA, USA), anti-CD14-FITC (Bio-
Legend), anti-CD1a-FITC (BioLegend), anti-CD19-FITC (BD Bio-
sciences, San Jose, CA, USA), anti-CD34-FITC (BioLegend), anti-TCR-
Pan-gd-FITC (Beckman Coulter, Miami, FL, USA), anti-CD123-FITC
(BioLegend), anti-BDCA2-FITC (BioLegend), anti-FC 3R1-FITC (Bio-
Legend), anti-CD3-APC-H7 (BD Biosciences), anti-Va7.2-PE (Bio-
Legend), anti-CD161-PerCPCy5.5 (BioLegend), anti-CD56-Alexa
Fluor 700 (BD Biosciences), anti-CD69-APC (BioLegend), anti-CD294innate lymphoid cells and mucosal-associated invariant T cells are
ternational (2016), http://dx.doi.org/10.1016/j.alit.2016.07.005
Table 1
Baseline characteristics of the study population.
Total
n ¼ 75





Sex (M/F), n (%) 30 (40.0)/45 (60.0) 17 (63.0)/10 (37.0) 13 (27.1)/35 (72.9) 0.025*
Age (y) 54.09 ± 16.73 59.00 ± 15.79 51.33 ± 16.76 0.056
Age at asthma onset (y) 39.57 ± 22.71 44.37 ± 21.85 36.88 ± 22.97 0.159
Body mass index (kg/cm2) 23.90 ± 4.87 23.44 ± 3.65 24.16 ± 5.46 0.950
Smoking history
(never/ex/current), n (%)
43 (57.3)/29 (38.7)/3 (4.0) 10 (37.0)/15 (55.6)/2 (7.4) 33 (68.8)/14 (29.2)/1 (2.1) 0.025*
Atopic dermatitis, n (%) 19 (25.3) 6 (22.2) 13 (27.1) 0.089
Allergic rhinitis, n (%) 49 (65.3) 16 (59.3) 33 (68.8) 0.455
Daily dose of inhaled corticosteroids
(FP equivalent dose, mg)
554.67 ± 404.38 151.85 ± 96.56 781.25 ± 326.59 <0.001*
Daily dose of oral corticosteroids,
n (PSL equivalent dose, mg)
5 (0.24 ± 1.29) 0 (0.00 ± 0.00) 5 (0.38 ± 1.61) 0.153
Asthma control test (ACT) score 23.42 ± 2.81 24.85 ± 0.46 22.60 ± 3.24 <0.001*
FVC (L) 3.32 ± 1.02 3.59 ± 1.01 3.16 ± 1.00 0.076
%FVC (%) 103.28 ± 17.42 106.47 ± 16.52 101.50 ± 17.83 0.221
FEV1 (L) 2.48 ± 0.84 2.56 ± 0.79 2.43 ± 0.86 0.522
%FEV1 (%) 91.92 ± 19.19 91.18 ± 17.17 92.33 ± 20.40 0.585
FEV1% (%) 74.44 ± 10.17 71.04 ± 7.36 76.35 ± 11.06 0.002*
PEF (L/s) 7.43 ± 2.00 7.93 ± 2.16 7.15 ± 1.87 0.106
%PEF (%) 103.49 ± 20.44 103.28 ± 18.05 103.61 ± 21.86 0.946
R5 (cmH2O/L/s) 3.45 ± 1.34 3.43 ± 1.39 3.47 ± 1.32 0.915
R20 (cmH2O/L/s) 2.90 ± 1.03 2.84 ± 1.05 2.94 ± 1.03 0.690
X5 (cmH2O/L/s) 0.69 ± 1.07 0.94 ± 1.57 0.55 ± 0.60 0.812
ALX (cmH2O/L/s) 4.19 ± 9.08 6.69 ± 14.06 2.78 ± 3.85 0.761
Fres (Hz) 8.38 ± 3.89 8.90 ± 4.91 8.08 ± 3.20 0.593
FeNO (ppb) 59.60 ± 48.48 68.95 ± 55.80 54.34 ± 43.57 0.046*
Peripheral eosinophils (/mL) 242.49 ± 213.63 253.30 ± 203.79 236.41 ± 220.85 0.512
Peripheral neutrophils (/mL) 3913.03 ± 1558.43 3284.17 ± 898.65 4266.77 ± 1738.45 0.016*
Serum IgE (IU/mL) 469.48 ± 1314.49 496.45 ± 722.38 454.31 ± 1559.23 0.083
Serum periostin (ng/mL) 89.36 ± 33.19 95.63 ± 26.54 85.83 ± 36.19 0.064
The data are presented as the mean ± the standard deviation, unless otherwise indicated.
Abbreviations for all tables: ACT, asthma control test; ALX, low-frequency reactance area; FeNO, fractional exhaled nitric oxide; FEV1%, forced expiratory volume in 1 s/forced
vital capacity; FEV1, forced expiratory volume in 1 s; Fres, resonant frequency; FVC, forced vital capacity; ILC, innate lymphoid cell; ILC1, group 1 innate lymphoid cell; ILC2,
group 2 innate lymphoid cell; ILC3, group 3 innate lymphoid cell; MAIT, mucosal-associated invariant T; NA, not applicable; NK, natural killer; PEF, peak expiratory ﬂow; R20,
respiratory resistance at 20 Hz; R5, respiratory resistance at 5 Hz; SE, standard error; X5, respiratory reactance at 5 Hz.
*Indicates p < 0.05, mild to moderate asthma versus severe asthma.
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let 605 (BioLegend), and anti-CD117 (c-Kit)-PE-CF594 (BD Bio-
sciences). Lineage marker negative (Lin) was deﬁned as CD1a,
CD3, CD11c, CD14, CD19, CD34, TCRgd, CD123, BDCA2, and
FC 3R1. Mucosal-associated invariant Tcellswere identiﬁed as CD3þ
Va7.2 TCRþ CD161high cells; NK cells, as CD3 CD56þ cells; ILC1, as
Lin CD127þ CD161þ CD117 CRTH2 cells; ILC2, as Lin CD127þ
CD161þ CRTH2þ cells; and ILC3, as Lin CD127þ CD161þ CD117þ
CRTH2 cells. The activation marker CD69 was analyzed in total
MAITcells, NK cells, and ILCs. After overnight ﬁxation, the cells were
analyzed by the ﬂuorescence-activated cell sorting (FACS) LSRFor-
tessa cell analyzer (BD Biosciences). The FACS data were analyzed
with Flowjo software (Version 7.6.5; Tree Star, Ashland, OR, USA).Table 2





NK cells (% of lymphocytes) 11.11 ± 6.37 1
ILC1 (% of Lin CD127þ CD161þ cells) 61.48 ± 12.88 6
ILC2 (% of Lin CD127þ CD161þ cells) 24.39 ± 12.75 2
ILC3 (% of Lin CD127þ CD161þ cells) 14.13 ± 5.97 1
MAIT cells (% of CD3þ cells) 2.21 ± 2.10 2
CD69þ NK cells (% of NK cells) 19.69 ± 6.60 2
CD69þ ILC1 (% of ILC1) 17.67 ± 6.61 1
CD69þ ILC2 (% of ILC2) 27.60 ± 7.99 2
CD69þ ILC3 (% of ILC3) 28.45 ± 14.42 2
CD69þ MAIT cells (% of MAIT cells) 27.51 ± 13.70 3
*Indicates p < 0.05.
The data are presented as the mean ± the standard deviation, unless otherwise indicate
Please cite this article in press as: Ishimori A, et al., Circulating activated
associated with airﬂow limitation in patients with asthma, Allergology InQuantiﬁcation of the periostin serum level
The sera of patients were collected by density-gradient centri-
fugation of blood samples and frozen at 80 C. Periostin levels
were measured with an enzyme-linked immunosorbent assay
(Shino-Test, Kanagawa, Japan), as described previously.32
Statistical analysis
Sample normality was examined using the D'Agostino and
Pearson test. Differences in parameters between populations were
analyzed for signiﬁcance using the Student t test, ManneWhitney U





0.08 ± 5.42 11.69 ± 6.83 0.406
1.97 ± 12.50 61.21 ± 13.22 0.574
2.20 ± 12.79 25.62 ± 12.69 0.163
5.83 ± 5.79 13.17 ± 5.91 0.064
.01 ± 1.66 2.32 ± 2.32 0.932
0.02 ± 6.25 19.51 ± 6.85 0.537
7.10 ± 4.77 17.99 ± 7.48 0.778
6.36 ± 5.74 28.30 ± 8.99 0.859
6.62 ± 7.99 29.48 ± 17.10 0.761
1.88 ± 15.28 25.05 ± 12.21 0.037*
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Table 4
The correlation between circulating MAIT cells, after adjusting for age.
Log MAIT cells
Single Age-adjusted
b SE P value b SE P value
Age (y) 0.014 0.003 <0.001* NA NA NA
Age at asthma onset (y) 0.008 0.002 0.001* 0.000 0.003 0.899
BMI (kg/cm2) 0.028 0.010 0.008* 0.027 0.009 0.003*
Daily dose of inhaled
corticosteroids
(FP equivalent dose, mg)
0.000 0.000 0.781 0.000 0.000 0.331
Daily dose of oral
corticosteroids
(PSL equivalent dose, mg)
0.022 0.036 0.546 0.010 0.031 0.741
ACT (score) 0.009 0.019 0.651 0.011 0.016 0.510
FVC (L) 0.186 0.047 <0.001* 0.080 0.052 0.133
%FVC (%) 0.002 0.003 0.530 0.001 0.003 0.632
FEV1% (%) 0.007 0.005 0.202 0.005 0.005 0.334
FEV1 (L) 0.236 0.057 <0.001* 0.076 0.073 0.301
%FEV1 (%) 0.000 0.003 0.882 0.002 0.002 0.488
PEF (L/s) 0.095 0.024 <0.001* 0.047 0.025 0.065
%PEF (%) 0.001 0.003 0.583 0.001 0.002 0.699
R5 (cmH2O/L/s) 0.091 0.382 0.020* 0.059 0.034 0.082
R20 (cmH2O/L/s) 0.107 0.050 0.036* 0.084 0.043 0.054
X5 (cmH2O/L/s) 0.069 0.049 0.166 0.035 0.047 0.460
ALX (cmH2O/L/s) 0.004 0.006 0.452 0.008 0.005 0.163
Fres (Hz) 0.034 0.013 0.012* 0.008 0.013 0.512
FeNO (ppb) 0.000 0.001 0.772 0.000 0.001 0.970
Peripheral eosinophils (/mL) 0.000 0.000 0.338 0.000 0.000 0.500
Peripheral neutrophils (/mL) 0.000 0.000 0.760 0.000 0.000 0.355
Serum IgE (IU/mL) 0.000 0.000 0.854 0.000 0.000 0.330
Serum periostin (ng/mL) 0.004 0.002 0.006* 0.003 0.001 0.067
NK cells (% of lymphocytes) 0.002 0.008 0.813 0.006 0.007 0.419
ILC1 (% of Lin CD127þ
CD161þ cells)
0.005 0.004 0.212 0.006 0.003 0.105
ILC2 (% of Lin CD127þ
CD161þ cells)
0.006 0.004 0.173 0.005 0.003 0.124
ILC3 (% of Lin CD127þ
CD161þ cells)
0.002 0.009 0.833 0.002 0.008 0.833
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Spearman's rank correlation coefﬁcient were used where appro-
priate. Differences were statistically signiﬁcant when the p values
were 0.05 or less. Statistical analyses were performed by version 6 of
Graph Pad Prism software (GraphPad Software, La Jolla, CA, USA).
The relationships between the parameters and the MAIT cells were
assessed by age-adjusted and unadjusted regression analysis using
STATA12.1 software (STATACorporation LP, College Station, TX, USA).
Results
Baseline characteristics
Seventy-ﬁve patients with asthma were enrolled in this study.
The baseline characteristics of eligible patients are summarized in
Table 1. The male to female ratio was 30:45, and the mean age was
54.09 ± 16.73 years. The mean duration of asthma was 14.5 ± 15.1
years, and the mean FEV1% which is calculated by FEV1/the forced
vital capacity (FVC) was 74.44% ± 10.17%. Table 1 shows the pa-
tients' baseline characteristics separated by the severity of asthma,
which was assessed in accordance with the GINA guidelines.30
Forty eight patients with severe asthma were compared to 27 pa-
tients who had mild to moderate asthma. The male to female ratio,
the ACT score, and the FeNO levels in the severe asthmatic group
were signiﬁcantly lower, whereas the never-smoker/current and
ex-smoker ratio, the daily dose of inhaled corticosteroids, the
FEV1%, and the peripheral neutrophil counts in the severe asth-
matic group were signiﬁcantly higher.
Circulating innate subsets of lymphoid cells in patients with asthma
We examined the frequency of ILCs and MAIT cells in the pe-
ripheral blood of patients with asthma by using ﬂow cytometry.Table 3
The correlation between the circulating innate subsets of lymphoid cells.
NK cells ILC1 ILC2 ILC3 MAIT cells
r P value r P value r P value r P value r P value
Age (y) 0.135 0.250 0.044 0.707 0.007 0.952 0.103 0.381 0.528 <0.001*
Age at asthma onset (y) 0.167 0.154 0.061 0.603 0.029 0.802 0.048 0.680 0.385 <0.001*
BMI (kg/cm2) 0.044 0.706 0.089 0.448 0.174 0.136 0.262 0.023* 0.265 0.022*
Daily dose of inhaled
corticosteroids (FP equivalent dose, mg)
0.024 0.836 0.025 0.829 0.081 0.491 0.110 0.347 0.028 0.810
Daily dose of oral
corticosteroids (PSL equivalent dose, mg)
0.008 0.947 0.329 0.004* 0.250 0.031* 0.248 0.032* 0.078 0.504
ACT (score) 0.083 0.483 0.172 0.143 0.101 0.392 0.239 0.040* 0.049 0.680
FVC (L) 0.030 0.798 0.141 0.228 0.049 0.679 0.173 0.139 0.408 <0.001*
%FVC (%) 0.269 0.020* 0.119 0.310 0.024 0.839 0.261 0.024* 0.105 0.371
FEV1% (%) 0.060 0.609 0.005 0.963 0.083 0.480 0.177 0.130 0.196 0.093
FEV1 (L) 0.063 0.590 0.135 0.248 0.081 0.491 0.079 0.503 0.474 <0.001*
%FEV1 (%) 0.247 0.033* 0.093 0.425 0.017 0.885 0.103 0.379 0.036 0.762
PEF (L/s) 0.025 0.832 0.168 0.149 0.100 0.395 0.201 0.084 0.450 <0.001*
%PEF (%) 0.195 0.093 0.086 0.464 0.003 0.978 0.159 0.174 0.050 0.670
R5 (cmH2O/L/s) 0.043 0.714 0.094 0.425 0.065 0.579 0.047 0.692 0.259 0.025*
R20 (cmH2O/L/s) 0.017 0.883 0.102 0.386 0.083 0.479 0.080 0.494 0.249 0.031*
X5 (cmH2O/L/s) 0.090 0.442 0.159 0.174 0.112 0.338 0.094 0.424 0.342 0.003*
ALX (cmH2O/L/s) 0.098 0.404 0.156 0.180 0.115 0.326 0.074 0.526 0.358 0.002*
Fres (Hz) 0.117 0.318 0.157 0.178 0.120 0.307 0.076 0.516 0.327 0.004*
FeNO (ppb) 0.195 0.094 0.102 0.385 0.089 0.449 0.001 0.995 0.078 0.504
Peripheral eosinophils (/mL) 0.149 0.202 0.087 0.459 0.177 0.129 0.130 0.268 0.161 0.167
Peripheral neutrophils (/mL) 0.105 0.371 0.141 0.228 0.080 0.494 0.116 0.323 0.048 0.681
Serum IgE (IU/mL) 0.070 0.553 0.202 0.083 0.180 0.123 0.026 0.822 0.059 0.616
Serum periostin (ng/mL) 0.117 0.320 0.002 0.984 0.006 0.959 0.065 0.578 0.301 0.009*
NK cells (% of lymphocytes) NA NA 0.047 0.690 0.166 0.156 0.195 0.093 0.062 0.595
ILC1 (% of Lin CD127þ CD161þ cells) 0.047 0.690 NA NA 0.881 <0.001* 0.254 0.028* 0.140 0.231
ILC2 (% of Lin CD127þ CD161þ cells) 0.166 0.156 0.881 <0.001* NA NA 0.155 0.184 0.154 0.186
ILC3 (% of Lin CD127þ CD161þ cells) 0.195 0.093 0.254 0.028* 0.155 0.184 NA NA 0.028 0.814
MAIT cells (% of CD3þ cells) 0.062 0.595 0.140 0.231 0.154 0.186 0.028 0.814 NA NA
*Indicates p < 0.05.
*Indicates p < 0.05.
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A. Ishimori et al. / Allergology International xxx (2016) 1e8 5The gating strategy for PBMCs is shown in Supplementary Figure 1.
In this study, the frequencies of NK cells and MAIT cells were
demonstrated by the ratio of CD3 CD56þ cells to lymphocytes and
the ratio of CD3þ Va7.2 TCRþ CD161high cells to CD3þ cells,
respectively. The frequencies of ILC1s, ILC2s, and ILC3s were also
shown by the ratio of Lin CD127þ CD161þ CD117 CRTH2 cells to
Lin CD127þ CD161þ cells, Lin CD127þ CD161þ CRTH2þ cells to
Lin CD127þ CD161þ cells, and Lin CD127þ CD161þ CD117þ
CRTH2 cells to Lin CD127þ CD161þ cells, respectively. The fre-
quencies of NK cells (mean, 11.11% ± 6.37%), ILC1s (mean,
61.48% ± 12.88%), ILC2s (mean, 24.39% ± 12.75%), ILC3s (mean,
14.13% ± 5.97%), and MAIT cells (mean, 2.21% ± 2.10%) were
detected in the peripheral blood of patients with asthma (Table 2).
There were no signiﬁcant differences between the asthma severity
groups in the frequencies of NK cells, ILC1s, ILC2s, ILC3s, and MAIT
cells (Table 2).
We next examined the cell surface expression of the activation
marker CD69 on NK cells, ILCs, and MAIT cells. The expression of
CD69, which is a member of the C-type lectin super-family, sug-
gests the activation of each innate subset of lymphoid cells.24,33,34
The percentages of CD69þ NK cells, ILCs, and MAIT cells are
shown in Table 2. The percentage of CD69þ MAIT cells in the pe-
ripheral blood is lower in patients with severe asthma than in pa-
tients with mild to moderate asthma (Table 2). Human NK cells can
be divided into two subsets: CD56bright NK cells (which produce
immunoregulatory cytokines such as IFN-g, IL-10, and IL-13) and
CD56dim NK cells (which represent a fully mature highly cytotoxic
NK cell subset).35 There were also no signiﬁcant differencesTable 5
The correlation between circulating CD69þ innate subsets of lymphoid cells.
CD69þ NK cells CD69þ ILC1
r P value r P valu
Age (y) 0.124 0.289 0.102 0.38
Age at asthma onset (y) 0.123 0.294 0.049 0.67
BMI (kg/cm2) 0.033 0.780 0.101 0.39
Daily dose of inhaled corticosteroids
(FP equivalent dose, mg)
0.108 0.356 0.023 0.84
Daily dose of oral corticosteroids
(PSL equivalent dose, mg)
0.023 0.842 0.031 0.79
ACT (score) 0.090 0.446 0.122 0.30
FVC (L) 0.275 0.017* 0.190 0.10
%FVC (%) 0.062 0.600 0.104 0.37
FEV1% (%) 0.242 0.037* 0.316 0.00
FEV1 (L) 0.170 0.144 0.065 0.57
%FEV1 (%) 0.154 0.188 0.323 0.00
PEF (L/s) 0.147 0.209 0.027 0.82
%PEF (%) 0.280 0.015* 0.431 <0.00
R5 (cmH2O/L/s) 0.090 0.445 0.016 0.89
R20 (cmH2O/L/s) 0.083 0.480 0.016 0.89
X5 (cmH2O/L/s) 0.063 0.592 0.058 0.62
ALX (cmH2O/L/s) 0.074 0.526 0.060 0.60
Fres (Hz) 0.042 0.722 0.056 0.63
FeNO (ppb) 0.059 0.615 0.201 0.08
Peripheral eosinophils (/mL) 0.074 0.528 0.063 0.59
Peripheral neutrophils (/mL) 0.014 0.907 0.023 0.84
Serum IgE (IU/mL) 0.121 0.301 0.148 0.20
Serum periostin (ng/mL) 0.070 0.552 0.082 0.48
NK cells (% of lymphocytes) 0.069 0.556 0.269 0.02
ILC1 (% of Lin CD127þ CD161þ cells) 0.203 0.081 0.049 0.67
ILC2 (% of Lin CD127þ CD161þ cells) 0.169 0.148 0.148 0.20
ILC3 (% of Lin CD127þ CD161þ cells) 0.047 0.688 0.226 0.05
MAIT cells (% of CD3þ cells) 0.147 0.209 0.079 0.49
CD69þ NK cells (% of NK cells) NA NA 0.686 <0.00
CD69þ ILC1 (% of ILC1) 0.686 <0.001* NA NA
CD69þ ILC2 (% of ILC2) 0.424 <0.001* 0.589 <0.00
CD69þ ILC3 (% of ILC3) 0.376 <0.001* 0.628 <0.00
CD69þ MAIT cells (% of MAIT cells) 0.468 <0.001* 0.503 <0.00
*Indicates p < 0.05.
Please cite this article in press as: Ishimori A, et al., Circulating activated
associated with airﬂow limitation in patients with asthma, Allergology Inbetween the asthma severity groups in the frequencies of
CD56bright and CD56dim NK cells and the percentages of CD69þ
CD56bright and CD56dim NK cells (Supplementary Table 1).
Correlation between the circulating innate subsets of lymphoid cells
The frequency of NK cells was negatively correlated with
percent predicted FVC (%FVC) and percent predicted FEV1 (%FEV1)
(Table 3). The frequency of CD56bright NK cells was negatively
correlated with age, percent predicted PEF (%PEF), low-frequency
reactance area (ALX), and resonant frequency (Fres), and posi-
tively correlated with respiratory reactance at 5 Hz (X5) and the
frequency of MAIT cells (Supplementary Table 2). The frequency of
CD56dim NK cells was negatively correlated with %FVC and %FEV1
and positively correlated with the frequency of total NK cells
(Supplementary Table 2). The daily dose of oral corticosteroids was
positively correlated with the frequency of ILC1s and negatively
correlated with the frequencies of ILC2s and ILC3s (Table 3). The
frequency of ILC1s was negatively correlated with the frequencies
of ILC2s and ILC3s (Table 3). The frequency of ILC3s was negatively
correlated with BMI and positively correlated with ACT score and %
FVC (Table 3). The frequency of peripheral blood MAIT cells in
asthmatics was adjusted for age using multiple regression analysis
because the frequency of peripheral blood MAIT cells and the total
peripheral blood MAIT cells reportedly decreases with age.36,37 The
frequency of peripheral blood MAIT cells in asthmatic patients was
negatively correlated with age, the age of asthma onset, and airﬂow
limitation, before adjusting for age using multiple regressionCD69þ ILC2 CD69þ ILC3 CD69þ MAIT cells
e r P value r P value r P value
4 0.065 0.580 0.023 0.842 0.179 0.124
4 0.033 0.781 0.034 0.773 0.112 0.337
0 0.164 0.160 0.275 0.017* 0.055 0.641
7 0.066 0.572 0.018 0.879 0.187 0.109
0 0.149 0.201 0.026 0.824 0.134 0.250
0 0.082 0.486 0.024 0.838 0.126 0.283
3 0.014 0.906 0.005 0.964 0.100 0.393
3 0.137 0.241 0.006 0.961 0.049 0.676
6* 0.236 0.041* 0.149 0.202 0.247 0.033*
8 0.057 0.630 0.050 0.668 0.013 0.910
5* 0.281 0.015* 0.071 0.543 0.157 0.178
0 0.029 0.803 0.044 0.709 0.050 0.668
1* 0.200 0.085 0.094 0.421 0.220 0.058
3 0.026 0.827 0.033 0.777 0.022 0.854
2 0.023 0.847 0.007 0.950 0.031 0.792
0 0.070 0.552 0.105 0.373 0.046 0.696
7 0.077 0.510 0.104 0.376 0.060 0.607
5 0.097 0.410 0.118 0.314 0.068 0.560
4 0.110 0.350 0.006 0.956 0.116 0.321
1 0.019 0.870 0.077 0.513 0.057 0.627
4 0.055 0.642 0.085 0.470 0.058 0.623
5 0.102 0.385 0.001 0.992 0.132 0.259
3 0.002 0.988 0.012 0.919 0.042 0.720
0* 0.183 0.116 0.013 0.909 0.121 0.303
4 0.121 0.301 0.010 0.932 0.087 0.458
7 0.040 0.731 0.171 0.142 0.087 0.456
2 0.285 0.013* 0.365 0.001* 0.068 0.563
9 0.019 0.875 0.059 0.612 0.148 0.204
1* 0.424 <0.001* 0.376 <0.001* 0.468 <0.001*
0.589 <0.001* 0.628 <0.001* 0.503 <0.001*
1* NA NA 0.468 <0.001* 0.218 0.060
1* 0.468 <0.001* NA NA 0.274 0.018*
1* 0.218 0.060 0.274 0.018* NA NA
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frequency of MAIT cells and age of asthma onset and airﬂow limi-
tation, after adjusting for age (Table 4).Correlation between circulating CD69þ-activated innate subsets of
lymphoid cells
The percentage of CD69þNK cells in the total NK cells of patients
with asthma was positively correlated with FVC and negatively
correlated with FEV1% and %PEF (Table 5). The percentage of CD69þ
ILC1s was negatively correlated with FEV1%, %FEV1, and %PEF
(Table 5). The percentage of CD69þ ILC2s was also negatively
correlated with FEV1% and %FEV1 (Table 5). The percentage of
CD69þ ILC3s was positively correlated with BMI, and the percent-
age of CD69þ MAIT cells was negatively correlated with FEV1%
(Table 5). The percentage of CD69þ CD56bright NK cells wasFig. 1. The percentage of CD69þ NK cells, ILC1s, ILC2s, ILC3s, MAIT cells positively
correlated each other. ILC1, group 1 innate lymphoid cell; ILC2, group 2 innate
lymphoid cell; ILC3, group 3 innate lymphoid cell; MAIT, mucosal-associated invariant
T; NK, natural killer.
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Table 3). The percentage of CD69þ CD56dim NK cells was positively
correlated with FVC and serum IgE levels and negatively correlated
with %PEF (Supplementary Table 3). The percentages of CD69þ NK
cells (including CD56bright and CD56dim NK cells), ILC1s, ILC2s,
ILC3s, and MAIT cells in these total cells were positively correlated
with each other except the correlation between CD69þ ILC2s and
MAIT cells (Table 5, Supplementary Table 3, Fig. 1). Moreover, even
after adjusting for age using multiple regression analysis, the per-
centage of CD69þ MAIT cells was correlated with %PEF, serum
periostin levels, and with the percentage of CD69þ NK cells, ILC1s,
and ILC3s (Table 6). Furthermore, the percentage of CD69þ MAIT
cells was correlated with the percentage of CD69þ ILC2s, after
adjusting for age (Table 6). These ﬁndings suggested that circu-
lating activated NK cells, ILC1s, ILC2s, ILC3s, and MAIT cells were
positively correlated with each other and may be associated with
airﬂow limitation in patients with asthma.Discussion
To our knowledge, this is the ﬁrst study to show that the CD69þ-
activated NK cells, ILC1s, ILC2s, ILC3s, andMAIT cells were positively
correlated with each other and associated with airﬂow limitation in
patients with asthma. Asthma is a heterogeneous inﬂammatory
disorder comprising distinct phenotypes, such as Th2-high asthma,
neutrophilic asthma, viral-induced asthma, and obesity-associated
asthma.4,38 In group 1 ILCs, which include traditional NK cells and
ILC1s, NK cells contribute to innate defense against viral infectionTable 6
The correlation between circulating CD69þ MAIT cells, after adjusting for age.
Log CD69þ MAIT cells
Single Age-adjusted
b SE P value b SE P value
Age (y) 0.003 0.002 0.103 NA NA NA
Age at asthma
onset (y)
0.001 0.001 0.416 0.001 0.002 0.544
BMI (kg/cm2) 0.005 0.006 0.427 0.005 0.006 0.394
Daily dose of inhaled
corticosteroids
(FP equivalent dose, mg)
0.000 0.000 0.042* 0.000 0.000 0.062
Daily dose of oral
corticosteroids
(PSL equivalent dose, mg)
0.012 0.019 0.543 0.014 0.019 0.463
ACT (score) 0.010 0.010 0.299 0.010 0.010 0.312
FVC (L) 0.017 0.027 0.535 0.059 0.031 0.065
%FVC (%) 0.000 0.002 0.840 0.000 0.002 0.901
FEV1% (%) 0.005 0.003 0.042* 0.004 0.003 0.143
FEV1 (L) 0.003 0.330 0.924 0.061 0.044 0.169
%FEV1 (%) 0.002 0.001 0.290 0.001 0.001 0.360
PEF (L/s) 0.005 0.014 0.710 0.007 0.016 0.635
%PEF (%) 0.003 0.001 0.042* 0.003 0.001 0.015*
FeNO (ppb) 0.001 0.001 0.229 0.001 0.001 0.189
Peripheral eosinophils (/mL) 0.000 0.000 0.960 0.000 0.000 0.930
Peripheral neutrophils (/mL) 0.000 0.000 0.946 0.000 0.000 0.916
Serum IgE (IU/mL) 0.000 0.000 0.547 0.000 0.000 0.702
Serum periostin (ng/mL) 0.001 0.001 0.116 0.002 0.001 0.036*
NK cells (% of lymphocytes) 0.005 0.004 0.249 0.004 0.004 0.314
ILC1 (% of Lin CD127þ
CD161þ cells)
0.002 0.002 0.270 0.002 0.002 0.284
ILC2 (% of Lin CD127þ
CD161þ cells)
0.002 0.002 0.251 0.003 0.002 0.237
ILC3 (% of Lin CD127þ
CD161þ cells)
0.000 0.005 0.952 0.001 0.005 0.840
CD69þ NK cells (% of NK cells) 0.017 0.004 <0.001* 0.018 0.004 <0.001*
CD69þ ILC1 (% of ILC1) 0.014 0.004 0.001* 0.015 0.004 <0.001*
CD69þ ILC2 (% of ILC2) 0.006 0.003 0.072 0.007 0.003 0.041*
CD69þ ILC3 (% of ILC3) 0.004 0.002 0.041* 0.004 0.002 0.034*
*Indicates p < 0.05.
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13 in the development of allergic asthma.39 Epithelial cell-derived
cytokines such as IL-33 was correlated with the Th2 cytokines and
provoked IL-13-producing ILC2s, which have a preeminent role in
asthma pathogenesis.29,40,41 Halim et al. have shown that ILC2s
regulated the differentiation of naive CD4þ T cells into Th2 cells.42
Moreover, it has been reported that IL-17- and IL-22-producing
ILC3s facilitate obesity-associated asthma.43,44 The correlation be-
tween BMI and the circulating activated ILC3s in this study may
reﬂect these reports that ILC3s mediates obesity-associated asthma.
The MAIT cells also can produce IL-17, which is a potent activator of
neutrophils, in human obesity and inmurinemodels of arthritis.10,45
Taken together, the positive correlation between activated NK cells,
ILC1s, ILC2s, ILC3s, andMAIT cells in asthma suggested that antigen-
speciﬁc Th2 cells and these innate subsets of lymphoid cells may
have a role in orchestrating asthmatic airway inﬂammation.
Several studies have shown that ILC2s in human peripheral
blood were signiﬁcantly increased in patients with asthma.46e48
Smith et al. have shown that absolute numbers of ILC2s, which
were identiﬁed as Lin CD45þ CD127þ ST2þ cells, were signiﬁcantly
increased in severe asthmatics, compared to mild asthmatics.46
Bartemes et al. also have demonstrated the total numbers of
ILC2s, which were identiﬁed Lin CD127þ CRTH2þ cells, were
signiﬁcantly increased in allergic asthmatics, compared to subjects
with allergic rhinitis and healthy control.47 Moreover, Liu et al. have
reported the frequency of ILC2s identiﬁed by the ratio of Lin
CD127þ CRTH2þ cells to peripheral blood lymphocytes were higher
in eosinophilic asthmatics, compared to noneosinophilic asth-
matics and healthy controls.48 However, Barnig et al. have
demonstrated that the frequency of ILC2s identiﬁed by the ratio of
Lin CD127þ CRTH2þ cells to Lin CD127þ cells in peripheral blood
was not different between healthy individuals, mild asthmatics,
and severe asthmatics.28 In the present study, there were no sig-
niﬁcant differences between the asthma severity groups in the
frequency of ILC2s identiﬁed by the ratio of Lin CD127þ CD161þ
CRTH2þ cells to Lin CD127þ CD161þ cells in peripheral blood. The
frequency of ILC2s identiﬁed by the ratio may lead to these
discrepant ﬁndings of asthmatics, because ratio can be inﬂuenced
by the frequency of other cell subsets and the subsets of ILC2s were
only a very small fraction.29 Barnig et al. also have demonstrated
CD69þ Lin CD56þ NK cells were increased in severe asthmatics,
compared to healthy individuals and mild asthmatics.28 Moreover,
the frequency of MAIT cells in the peripheral blood was decreased
in patients with severe asthma, multiple sclerosis, and inﬂamma-
tory bowel disease.9,24,36,49,50 Hinks et al. showed that decreased
MAIT cell frequencies in the peripheral blood and lung tissue were
correlated with severe asthma.9 By contrast, in the current study,
the peripheral blood NK cells, ILCs, and MAIT cells were not
correlated with asthma severity. It is acknowledged that a limita-
tion of current study was a lack of a healthy control group.
Furthermore, the baseline characteristics of eligible patients in this
study showed that the severe asthmatic group had lower FeNO
levels and higher peripheral neutrophil counts. These ﬁndings
suggest dominant neutrophilic airway inﬂammation. In addition,
FEV1% was higher in severe asthmatics than in mild to moderate
asthmatics. The reason for the lack of correlation between the
innate subsets of lymphoid cells and asthma severity and the high
FEV1% in severe asthmatics was not clear in the current study;
however, it may be related to their asthma treatment (e.g., oral and
inhaled corticosteroids) and to dominant neutrophilic airway
inﬂammation in patients with severe asthma. In any event, this
unique population subject may lead to discrepant ﬁndings between
previous studies and the current study. Further studies are needed
to investigate the association between the innate subsets of
lymphoid cells and asthma severity.Please cite this article in press as: Ishimori A, et al., Circulating activated
associated with airﬂow limitation in patients with asthma, Allergology InIn conclusion, to our knowledge, we have provided the ﬁrst
report that the CD69þ-activated NK cells, ILC1s, ILC2s, ILC3s, and
MAIT cells were positively correlated with each other, and high
activation of these cells may be associatedwith airﬂow limitation in
patients with asthma. All of these activated populations may
orchestrate immune responses, but not behave as an individual
population, in asthmatic airway inﬂammation. However, these
conclusions are limited by our small sample size. The innate subsets
of lymphoid cells in allergic asthma require further investigation.
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